Skip to contentC
Cardiff Oncology, Inc.
C
CRDFCardiff Oncology, Inc. Q3 2018 · 10-Q
Revenue$88.36K$88.36K−28.4% vs Q3 2017 Net Income-$3.77M-$3.77MN/M vs Q3 2017 EPS Diluted-$1.10-$1.10N/M vs Q3 2017 Operating Income-$3,855,308N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Cardiff Oncology, Inc. · CIK 1213037 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$3,479,479N/M Margins · derivedOperating margin-4363.1%+337.8 pt vs Q3 2017
Net margin-4266.1%−786.0 pt vs Q3 2017
ended Sep 30, 2018 · filed Nov 7, 2018 · 38 d after period end